Although preclinical data robustly suggest that DPP3 may mitigate hypertension and its related cardiovascular and renal complications, the lack of subsequent studies underscores the need for a more comprehensive mechanistic understanding and translational research before identifying this enzyme as a potential therapeutic target. This evidence concerns the gene DPP3 and hypertensive disorder.